中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
1期
8-10
,共3页
何兴端%朱金峰%冯应勤%鲁培
何興耑%硃金峰%馮應勤%魯培
하흥단%주금봉%풍응근%로배
CYP2C19%基因多态性%非小细胞肺癌%个体化用药
CYP2C19%基因多態性%非小細胞肺癌%箇體化用藥
CYP2C19%기인다태성%비소세포폐암%개체화용약
CYP2C19%Gene polymorphisms%Non-small cell lung cancer%Personalized medicine
目的 探讨CYP2C19基因多态性与非小细胞肺癌紫杉醇联合顺铂方案疗效和不良反应的关系.方法 通过基因芯片技术检测患者的CYP2C19的基因型,将患者分成EM组和PM组,比较两组之间疗效和不良反应的差异.结果 87例非小细胞肺癌患者中EM组65例(74.7％),PM组22例(25.3％),EM组和PM组的有效率分别为52.3％、50.0％,疾病控制率分别为81.3％、77.3％,两组比较差异无统计学意义(P＞0.05).EM组恶心、呕吐、肌肉或关节疼痛的发生率低于PM组(P＜0.05).结论 CYP2C19基因多态性影响紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的不良反应,未发现对近期疗效的影响.
目的 探討CYP2C19基因多態性與非小細胞肺癌紫杉醇聯閤順鉑方案療效和不良反應的關繫.方法 通過基因芯片技術檢測患者的CYP2C19的基因型,將患者分成EM組和PM組,比較兩組之間療效和不良反應的差異.結果 87例非小細胞肺癌患者中EM組65例(74.7％),PM組22例(25.3％),EM組和PM組的有效率分彆為52.3％、50.0％,疾病控製率分彆為81.3％、77.3％,兩組比較差異無統計學意義(P＞0.05).EM組噁心、嘔吐、肌肉或關節疼痛的髮生率低于PM組(P＜0.05).結論 CYP2C19基因多態性影響紫杉醇聯閤順鉑方案治療晚期非小細胞肺癌的不良反應,未髮現對近期療效的影響.
목적 탐토CYP2C19기인다태성여비소세포폐암자삼순연합순박방안료효화불량반응적관계.방법 통과기인심편기술검측환자적CYP2C19적기인형,장환자분성EM조화PM조,비교량조지간료효화불량반응적차이.결과 87례비소세포폐암환자중EM조65례(74.7％),PM조22례(25.3％),EM조화PM조적유효솔분별위52.3％、50.0％,질병공제솔분별위81.3％、77.3％,량조비교차이무통계학의의(P＞0.05).EM조악심、구토、기육혹관절동통적발생솔저우PM조(P＜0.05).결론 CYP2C19기인다태성영향자삼순연합순박방안치료만기비소세포폐암적불량반응,미발현대근기료효적영향.
Objective To investigate the relationship between CYP2C19 gene polymorphisms and the drug efficacy and adverse drug reactions of paclitaxel and cisplatin for non-small cell lung cancer (NSCLC).Methods Gene chip technology was used to detect the polymorphisms of CYP2C19 in nonsmall cell lung cancer patients.Patients were divided into EM group and PM group according to CYP2C19 genotype.The differences of drug efficacy and adverse reactions between the two groups were compared.Results In the 87 patients with non small cell lung cancer,65 cases (74.4％)were EMs,22 cases (25.5％) were PMs.The overall response rates of EM group and PM groups were 52.3％ and 50.0％,the disease control rates were 81.3％ and 77.3％ (P ＞ 0.05).The incidence rates of nausea,vomitting,muscle soreness in EM group were lower than those in PM group (P ＜ 0.05).Conclusions The gene polymorphisms of CYP2C19 can not affect the curative effect of paclitaxel and cisplatin on non-small cell lung cancer,but it can affect the adverse drug reactions.
